BRD4, a reader of histone acetylation, serves as a therapeutic target in GBM, providing a novel research perspective on restoring the normal epigenetic profile of GBM cells and enhancing the treatment of malignant GBM [45]. Here, BRD4 is linked to glioblastoma.